News & Updates

Treatment with the selective serotonin reuptake inhibitor fluvoxamine may prevent hospitalization in outpatients presenting with symptoms of COVID-19 who have a high risk for disease progression, according to results of the TOGETHER trial.

Use of atorvastatin in adults with COVID-19 admitted to the intensive care unit (ICU) is safe but does not result in a marked decrease in the composite of venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or all-cause mortality, a study has shown.

Among patients with epilepsy, quality of life (QOL) declines with antiseizure medication (ASM) polytherapy, and this effect is mediated by depression and the side effects of ASMs, as reported in a study.